<DOC>
	<DOC>NCT02446353</DOC>
	<brief_summary>A Randomized, Open Label, Single dose, Cross-over, Phase I Trial to Investigate Safety and Pharmacokinetics of Apetrol ES and Megace® in Healthy Male Volunteers.</brief_summary>
	<brief_title>Pharmacokinetics and Safety Study of Apetrol ES</brief_title>
	<detailed_description>[Part 1] fasting [Part 2] fed</detailed_description>
	<mesh_term>Megestrol Acetate</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<criteria>Is a healty male between 20 and 55 years old. In a ± 20% than ideal body weight. [ideal body weight(kg) = height(cm)100) x 0.9 (Broca's rule) Subjects who are considered to be suitable in conducting the clinical trial in serum test, hematology test, hematochemical test, urine test and 12ECG result. Is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Agrees to use an adequate means of contraception during clinical trials Subject who has voluntarily decided to participate in this clinical trial and consented in writing. Is allergic against Megestrol acetate or other drugs (Aspirin, NSAIDs, Antibiotics, etc.) or against foods, or has an clinically serious allergic history. Subjects who have present condition or past history of any disease involving liver, kidney, nervous system, immune system, respiratory system, or endocrine system; hematologic and oncologic disease; cardiovascular disease; or psychiatric disorder (mood disorder, obsessivecompulsive disorder, etc. that may affect ADME of investigational medicinal products. In the vital signs measured in sitting position at the screening visit, subjects who have hypertension desease(a systolic blood pressure of ≥ 150 mmHg or a diastolic blood pressure of ≥ 100 mmHg). Diabetic patients or the patients who are abnormal of impaired glucose tolerance. The patients who have a history of Arterial Embolism. The patients who have a history of adrenal insufficiency like hypotension or nausea or vertigo or asthenia or etc. Subjects who have a history of drug abuse or shown positive reaction to drugs that may be abused from a urine drug screening Subjects who took any specialized drug or an herbal medication within 2 weeks before the date of first administration or took any over the counter (OTC) drug within 1 week (however, they may be included as subjects if appropriate depending on the investigator's discretion) Subjects who had whole blood donation within 2 months or component blood donation within 1 month before the clinical trial. Subjects who have abnormal diets that may affect ADME of investigational medicinal products. Subjects who have been drinking extremely alcohol and caffeine (more than caffeine 5 cups/day, soju 3 cups/day, beer 3 cups/day, liquors 2 cups/day, 10 cigarettes/day) or can't refrain from drinking during the clinical trial period. Subjects who had administration a barbiturates within 1 month before the date of first drug administration Subjects who already participated in other clinical trials within 2 months before this clinical trial. Subjects who are considered to be unsuitable in conducting the clinical trial for other reason at the principal investigator's discretionary judgment</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Male Volunteers</keyword>
</DOC>